![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 15, 2019 4:53:57 PM
agree with them
A little color .........
Ignacio Melero
Results of the CheckMate 040 Trial
discusses study findings on
nivolumab
dose escalation
and expansion in patients with advanced hepatocellular
Nivolumab is a checkpoint inhibitor, a type of immunotherapy drug designed to target the PD-1 protein receptor.Sep 25, 2018
Stefan Zimmermann, MD trial
Immune Checkpoint Inhibitors in the Management of Lung Cancer
Combined immunotherapies – potential and pitfalls
John B. Haanen
Improved Survival with Ipilimumab in Patients
with Metastatic Melanoma
Ipilimumab injection may cause severe or life-threatening side effects
Ipilimumab is a type of monoclonal antibody. This medicine is designed to boost the immune system. Normally, a protein called CTLA-4 helps to regulate the immune system by keeping its cells in check. Ipilimumab blocks the activity of CTLA-4, which frees the immune system to act against melanoma cells in the body.
Yervoy is a biologic therapy. It's a kind of man-made antibody (a monoclonal antibody) that blocks a crucial switch on immune cells called CTLA-4. Cancers use this switch to turn off the body's anticancer immune responses.
===================================================
===================================================
Cancer researchers worry immunotherapy may hasten growth of tumors in some patients
The patient’s case was one of a handful described last week in the journal Clinical Cancer
Research. Of the 155 cases studied, eight patients who had been fairly stable before immunotherapy treatment declined rapidly, failing the therapy within two months.
Six saw their tumors enter a hyperactive phase, where the tumors grew by
between 53 percent and 258 percent.
===================================================
===================================================
We have, however, observed a subset of patients who appear to be
"hyper-progressors,"
with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy, which was also recently reported by Institut Gustave Roussy.
The current study investigated potential genomic markers associated with "hyper-progression" after immunotherapy.
Method: Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing were analyzed (N=155)
Two of 10 patients with EGFR alterations were ---- also ---- hyper-progressors (53.6% and 125% increase in tumor size; 35.7- and 41.7-fold increase).
Conclusion:
Some patients with MDM2 family amplification or EGFR aberrations had poor clinical outcome and significantly increased rate of tumor growth after single-agent checkpoint (PD-1/PD-L1) inhibitors.
Genomic profiles may help to identify patients at risk for hyper-progression on immunotherapy.
Further investigation is urgently needed.
Read Me
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM